Kathiawad Today

Chronic Pancreatitis Pipeline Insight, Emerging Drugs, and Clinical Trials Report 2023 | Key Companies – CalciMedica, GNT Pharma, Koligo Therapeutics, Kangen Pharmaceuticals, AzurRx SAS, and Others

 Breaking News
  • No posts were found

Chronic Pancreatitis Pipeline Insight, Emerging Drugs, and Clinical Trials Report 2023 | Key Companies – CalciMedica, GNT Pharma, Koligo Therapeutics, Kangen Pharmaceuticals, AzurRx SAS, and Others

May 23
06:55 2023
Chronic Pancreatitis Pipeline Insight, Emerging Drugs, and Clinical Trials Report 2023 | Key Companies - CalciMedica, GNT Pharma, Koligo Therapeutics, Kangen Pharmaceuticals, AzurRx SAS, and Others

DelveInsight’s, “Chronic Pancreatitis Pipeline Insight 2023” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Chronic Pancreatitis pipeline landscape. It covers the Chronic Pancreatitis pipeline drug profiles, including Chronic Pancreatitis clinical trials and nonclinical stage products. It also covers the Chronic Pancreatitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Recent Developmental Activities in the Chronic Pancreatitis Treatment Landscape

 

  • In January 2023, According to a joint statement from Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY), the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for the tablets Jardiance® (empagliflozin), which is being researched as a potential treatment to lower the risk of cardiovascular death and kidney disease progression in adults with chronic kidney disease (CKD).

 

Request a sample and discover the recent breakthroughs happening in the Chronic Pancreatitis Pipeline landscape @ Chronic Pancreatitis Pipeline Outlook

 

Chronic Pancreatitis Overview

Chronic pancreatitis is commonly defined as a continuing, chronic, inflammatory process of the pancreas, characterized by irreversible morphologic changes. Symptoms of chronic pancreatitis range widely and may include vomiting, constant dull, unremitting abdominal pain, epigastric tenderness, weight loss, steatorrhea and glucose intolerance.

 

Key Takeaways from the Chronic Pancreatitis Pipeline Report

 

  • DelveInsight’s Chronic Pancreatitis Pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Chronic Pancreatitistreatment.

 

  • The leading Chronic Pancreatitis Companies include CalciMedica, GNT Pharma, Koligo Therapeutics, Kangen Pharmaceuticals, AzurRx SAS, Theraly Fibrosis, Solvay Pharmaceuticals, Abbott, Axcan Pharma, TAP Pharmaceutical, Dompé Farmaceutici S.p.A, and others

 

  • Promising Chronic Pancreatitis Pipeline Therapies include Omeprazole, Viokase® 16, Reparixin, Panzytrat 25.000 FIP-E units of Lipase, Bupivicaine alone, Triamcinolone SA-001, Pancreatin, Creon, EUR-1008 (APT-1008) Low Dose, and others. 

 

  • The Chronic Pancreatitis companies and academics are working to assess challenges and seek opportunities that could influence Chronic Pancreatitis R&D. The Chronic Pancreatitis therapies under development are focused on novel approaches to treat/improve Chronic Pancreatitis.

 

For further information, refer to the detailed Chronic Pancreatitis Drugs Launch, Chronic Pancreatitis Developmental Activities, and Chronic Pancreatitis News, click here for Chronic Pancreatitis Ongoing Clinical Trial Analysis

 

Chronic Pancreatitis Emerging Drugs Profile

 

  • Oral CRAC channel inhibitors: CalciMedica

CalciMedica is developing oral CRAC channel inhibitors for chronic indications treated in an outpatient setting. The drug is in pre-clinical studies for the treatment of Chronic Pancreatitis.

 

  • NI-03: Kangen Pharmaceuticals

NI-03 (camostat mesilate) is an orally administered serine protease inhibitor that reduces pancreatic enzyme activity. The drug is in Phase I/II clinical studies for the treatment of Chronic Pancreatitis. The drug has been approved in Japan but has not been approved in the United States.

 

Chronic Pancreatitis Pipeline Therapeutics Assessment

There are approx. 6+ key companies which are developing the therapies for Chronic Pancreatitis. The companies which have their Chronic Pancreatitis drug candidates in the most advanced stage, i.e. Phase II include, AzurRx.

 

Find out more about the Chronic Pancreatitis Pipeline Segmentation, Therapeutics Assessment, and Chronic Pancreatitis Emerging Drugs @ Chronic Pancreatitis Treatment Landscape

 

Scope of the Chronic Pancreatitis Pipeline Report

 

  • Coverage- Global

 

  • Chronic Pancreatitis Companies- CalciMedica, GNT Pharma, Koligo Therapeutics, Kangen Pharmaceuticals, AzurRx SAS, Theraly Fibrosis, Solvay Pharmaceuticals, Abbott, Axcan Pharma, TAP Pharmaceutical, Dompé Farmaceutici S.p.A, and others

 

  • Chronic Pancreatitis Pipeline Therapies- Omeprazole, Viokase® 16, Reparixin, Panzytrat 25.000 FIP-E units of Lipase, Bupivicaine alone, Triamcinolone SA-001, Pancreatin, Creon, EUR-1008 (APT-1008) Low Dose, and others.

 

  • Chronic Pancreatitis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Chronic Pancreatitis Pipeline Companies and Therapies, click here @ Chronic Pancreatitis Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Chronic Pancreatitis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Chronic Pancreatitis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. MS1819-SD: AzurRx SAS
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Flusalazine: GNT Pharma
  15. Drug profiles in the detailed report…..
  16. Preclinical/Discovery Stage Products
  17. Oral CRAC inhibitor: CalciMedica
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Chronic Pancreatitis Key Companies
  21. Chronic Pancreatitis Key Products
  22. Chronic Pancreatitis- Unmet Needs
  23. Chronic Pancreatitis- Market Drivers and Barriers
  24. Chronic Pancreatitis- Future Perspectives and Conclusion
  25. Chronic Pancreatitis Analyst Views
  26. Chronic Pancreatitis Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Chronic Pancreatitis Mergers and acquisitions, Chronic Pancreatitis Licensing Activities @ Chronic Pancreatitis Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/